BioSpace News Archive

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced grants of inducement awards to its Chief Operating Officer, Brian Stolz; its Chief Accounting Officer, Yi Ching Yau; and one additional employee, on November 13, 2019.

Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company leveraging the microbiome to develop therapeutics designed to prevent and treat gastrointestinal (GI) diseases in areas of high unmet need, today announced it has received written communication from NYSE American LLC (the “Exchange”), the Company’s current listing exchange

GENOMICA, the molecular diagnostics company belonging to the PharmaMar Group (MSE:PHM), begins to materialize its first contract in China with the medical equipment company, HuaSin Science, to lead the global challenge of the early diagnosis of cervical cancer in China.

Nearly 90 percent survival for patients who received REGN-EB3 treatment earlier in the course of their disease; 66.5 percent survival among all patients who received REGN-EB3

Appili Therapeutics Inc., a biopharmaceutical company focused on anti-infective drug development, reported its financial and operational results for the second quarter of its fiscal year 2020, ending September 30, 2019.

Antares Pharma, Inc. announced that Robert F. Apple, President and Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference on Tuesday December 3, 2019 at 2:00 pm, Eastern Time.

Revive Therapeutics Ltd., a specialty cannabis company focused on the research, development, and commercialization of novel cannabinoid-based products, announced its results for the three months ended September 30, 2019.

Clover Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel and transformative biologic therapies, announced the completion of a US$ 43 million Series B financing.

Innovent Biologics, Inc. jointly announced with Eli Lilly and Company that the innovative PD-1 inhibitor Tyvyt®, co-developed by both companies, is the only PD-1 inhibitor that has been included in the new Catalogue of National Reimbursement Drug List according to the latest announcement from the National Healthcare Security Administration.

Azzur Welcomes Tita Tavares as Director of Its New Office in Washington, D.C.